University Of Maryland, Baltimore
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1807-01-01
- Employees
- 7.3K
- Market Cap
- -
- Website
- http://www.umaryland.edu
Dielectric Properties of Matched Tissue Samples From Thoracic Malignancies and Corresponding Normal Tissues
Not Applicable
- Conditions
- Mesothelioma; LungLung CancerEsophageal Cancer
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 30
- Registration Number
- NCT04804410
Improving Glycemic Control in DM2 Patients in the Ambulatory Setting
Not Applicable
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- Other: Point of Care Glucose GroupDevice: Smart insulin pens and CGM
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 30
- Registration Number
- NCT04800471
- Locations
- 🇺🇸
Baltimore VA Medical Center, Baltimore, Maryland, United States
ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
Phase 1
Completed
- Conditions
- Dengue
- Interventions
- Biological: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 17
- Registration Number
- NCT04786457
- Locations
- 🇺🇸
University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States
Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas
Phase 1
Recruiting
- Conditions
- Glioma
- Interventions
- Drug: Hyperpolarized 13C-Pyruvate
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 5
- Registration Number
- NCT04772456
- Locations
- 🇺🇸
Rosy Njonkou Tchoquessi, Baltimore, Maryland, United States
Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 200
- Registration Number
- NCT04706130
- Locations
- 🇰🇭
Institut Pasteur du Cambodge, Phnom Penh, Cambodia
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
Phase 2
Recruiting
- Conditions
- Prostate Cancer
- Interventions
- Drug: Hyperpolarized 13C-Pyruvate
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 20
- Registration Number
- NCT04698564
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
Not Applicable
Recruiting
- Conditions
- GlioblastomaBrain TumorGlioma
- Interventions
- Procedure: LITTRadiation: Hypofractionated Radiation Therapy
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 32
- Registration Number
- NCT04699773
- Locations
- 🇺🇸
Maryland Proton Treatment Center, Baltimore, Maryland, United States
🇺🇸University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸UCH Kaufman Cancer Center, Bel Air, Maryland, United States
Teletherapy for Upper Extremity Fracture Rehabilitation (TELE-REHAB Study)
Not Applicable
Withdrawn
- Conditions
- Upper Limb SurgeryOccupational Therapy
- Interventions
- Other: occupational therapy
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT04691739
- Locations
- 🇺🇸
U of Maryland, Baltimore, Maryland, United States
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
Phase 1
Active, not recruiting
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 27
- Registration Number
- NCT04666649
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition
Phase 4
Completed
- Conditions
- Polysorbate 80Bile Salt Export Pump (BSEP) Transporter
- Interventions
- Drug: pravastatin and chenodeoxycholic acid, after metformin and placeboDrug: valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 18
- Registration Number
- NCT04640571
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath